Vabra Aspirator — NCD 173 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 173 governing Vabra aspirator coverage, effective March 7, 2026. The core rule hasn't changed in its clinical logic, but billing teams need to understand exactly where the line is — because claims for asymptomatic patients will be denied, full stop.

CMS modified NCD 173 — the National Coverage Determination governing Medicare coverage of the Vabra aspirator — with an effective date of March 7, 2026. This policy applies to outpatient hospital diagnostic services and diagnostic tests billed in connection with uterine tissue sampling for endometrial carcinoma detection. The CMS Vabra aspirator coverage policy does not list specific CPT or HCPCS codes in the current policy data, which we'll address directly in the codes section below.

The real issue with NCD 173 is straightforward but unforgiving: Medicare pays for the Vabra aspirator and related diagnostic services only when the patient shows clinical symptoms. No symptoms, no coverage. That line will cut claims cleanly if your documentation doesn't hold up.

CMS Vabra Aspirator Coverage Criteria and Medical Necessity Requirements 2026

The Centers for Medicare & Medicaid Services defines the Vabra aspirator as a sterile, disposable vacuum aspirator used to collect uterine tissue for laboratory study. Its specific purpose is detecting endometrial carcinoma.

Medical necessity under NCD 173 requires the patient to exhibit clinical symptoms or signs suggestive of endometrial disease. CMS gives two explicit examples: irregular vaginal bleeding and heavy vaginal bleeding. Both are symptomatic presentations — your documentation needs to reflect one or both before Vabra aspirator billing will survive review.

This is not a policy where prior authorization is a factor — CMS doesn't list a prior authorization requirement for this service. But the absence of a prior auth requirement doesn't mean claims slip through unchecked. The medical necessity standard is enforced at the claim level, through documentation review and potential audits.

The coverage policy is clear on the category: Diagnostic Services in Outpatient Hospital and Diagnostic Tests (other). If your practice bills this service from a physician office or other setting, confirm that the benefit category maps correctly to your place of service. Reimbursement depends on it.

One thing to flag: the policy cross-references NCD 230.5 (the Gravlee Jet Washer) and Chapter 16, §90 of the Medicare Benefit Policy Manual. If your practice bills for both uterine tissue collection methods, review NCD 230.5 separately. The coverage logic is similar, but they're distinct policy instruments and you need to treat them that way.

CMS Vabra Aspirator Exclusions and Non-Covered Indications

This section is short — because CMS makes the exclusion explicit and binary.

Medicare will not pay for the Vabra aspirator or related diagnostic services when the examination involves an asymptomatic patient. CMS cites §1862(a)(7) of the Social Security Act, which prohibits payment for routine physical checkups. A Vabra aspirator used during a routine gynecologic exam on a patient with no symptoms is a routine checkup in CMS's view — and therefore not a covered service.

This is the claim denial risk that should keep your billing team alert. If a provider orders the Vabra aspirator as a precautionary screen — without documented clinical symptoms — the claim is not payable under Medicare. It doesn't matter how skilled the clinical reasoning is. If the chart doesn't show symptoms, the claim doesn't qualify.

The exclusion also applies to the related diagnostic services, not just the device itself. That means the laboratory analysis of the collected tissue sample is also non-covered when the patient is asymptomatic. One symptomatic finding in the record covers the whole encounter. One missing symptom documentation sinks the whole encounter.

Coverage Indications at a Glance

CMS Vabra Aspirator Billing Guidelines and Action Items 2026

These are the steps your billing team should take before and after the effective date of March 7, 2026.

CPT, HCPCS, and ICD-10 Codes for Vabra Aspirator Under NCD 173

The current NCD 173 policy data does not list specific CPT, HCPCS Level II, or ICD-10-CM codes. This is not unusual for older NCDs — CMS sometimes issues coverage determinations without binding a specific code set, leaving code-level specificity to local coverage determination (LCD) policies issued by Medicare Administrative Contractors (MACs).

What This Means for Your Billing Team

Your MAC may have issued an LCD or billing article that assigns specific procedure codes to Vabra aspirator claims in your region. Check your MAC's website directly — search for "Vabra aspirator" or "endometrial tissue collection" in their LCD and article databases.

Because NCD 173 doesn't specify codes, the national policy defines coverage criteria (symptomatic patient, endometrial disease workup) while your MAC defines the code-level billing instructions. That two-layer structure is common in Medicare, and it means you can't fully build out your charge capture just from this NCD alone.

The relevant ICD-10-CM diagnosis codes for this service will typically reflect symptomatic presentations: abnormal uterine bleeding, postmenopausal bleeding, or other signs suggestive of endometrial disease. Your MAC's LCD or billing article should specify which diagnosis codes support coverage. If you're not sure which MAC covers your jurisdiction, the CMS MAC jurisdiction map is the starting point.

If no MAC-level LCD exists for this service in your region, you're working from the NCD alone — which means the symptomatic documentation standard in NCD 173 is your only binding coverage rule. Document accordingly.